Carol Krantz

Carol Krantz is Sr. Director and Head of the Regulatory Affairs, CMC group at Seagen Inc. She received a B.A. in Biology from the University of Pennsylvania and a Ph.D. in Immunology/Microbiology from the University of Colorado before locating to Seattle to conduct post-doctoral studies at the Fred Hutchinson Cancer Research Center in the area of immune responses to virally transformed cells. Carol has worked in biotech for over 25 years, 19 years of which have been in Regulatory Affairs at Amgen, Sierra Oncology and Seagen. Since joining Seagen in 2017, she has built the Regulatory CMC group which helped gain U.S. approval for PADCEV via the BTD pathway and more recently, approval of TUKYSA in the U.S., Canada, Switzerland, Singapore and Australia as one of the first new molecular entities to participate in Project Orbis.